Gleeson N C, Fiorica J V, Mark J E, Pinelli D M, Hoffman M S, Roberts W S, Cavanagh D
Department of Obstetrics & Gynecology, Tampa General Hospital, University of South Florida.
Gynecol Oncol. 1993 Dec;51(3):372-6. doi: 10.1006/gyno.1993.1306.
There is a demand on gynecologic oncology services for semipermanent cannulization of central veins to improve the quality of life in cancer patients by circumventing the need for frequent peripheral venous punctures. Central venous thrombosis and sepsis are the major complications with these lines. We reviewed our experience with the externalized Groshong catheters and subcutaneously implanted Hickman ports in 104 gynecologic oncology patients requiring either chemotherapy (56), hyperalimentation (5), or supportive care (43). All devices were inserted under the supervision of one primary gynecologic oncologist. Groshong catheters and Hickman ports remained in place for a median of 68.5 and 210 days, respectively (P < 0.001). Thrombosis occurred in association with 4.8% of catheters and was exclusive to the Groshong catheters. Line sepsis occurred in 32% of Groshong catheters and 16.2% of Hickman ports (P = 0.04). Infection rates were not higher in dual-lumen compared to single-lumen Groshong catheters. Staphylococcus epidermidis was the comments isolate in line infections. The majority of lines were salvaged despite infectious complications. Malfunction of the catheter was equally common in both groups (10.5-13.5%), but was complete, necessitating replacement of only 2.9% of lines. The Groshong catheters took less time to insert (P < 0.003). The externalized Groshong catheter remains a useful alternative to the subcutaneously implanted ports, especially when relatively short-term use is anticipated, but gynecologic oncologists should be aware that there is an increased frequency of complications with the externalized catheter.
为了避免频繁的外周静脉穿刺以提高癌症患者的生活质量,妇科肿瘤学服务领域对中心静脉半永久性置管存在需求。中心静脉血栓形成和败血症是这些置管的主要并发症。我们回顾了104例需要化疗(56例)、胃肠外营养(5例)或支持治疗(43例)的妇科肿瘤患者使用外置Groshong导管和皮下植入Hickman端口的经验。所有装置均在一位主要的妇科肿瘤学家的监督下插入。Groshong导管和Hickman端口分别中位留置68.5天和210天(P<0.001)。4.8%的导管发生血栓形成,且仅发生于Groshong导管。32%的Groshong导管和16.2%的Hickman端口发生导管败血症(P=0.04)。双腔Groshong导管的感染率并不高于单腔Groshong导管。表皮葡萄球菌是导管感染中最常见的分离菌。尽管有感染并发症,但大多数导管得以挽救。两组中导管故障同样常见(10.5%-13.5%),但完全故障仅占2.9%,需要更换导管。Groshong导管插入所需时间较短(P<0.003)。外置Groshong导管仍是皮下植入端口的一种有用替代方法,尤其是预期使用时间相对较短时,但妇科肿瘤学家应意识到外置导管的并发症发生率会增加。